{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:54:50Z","timestamp":1790985290251,"version":"4.1.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This prospective, dose-escalation phase I study evaluated the safety and efficacy of intraperitoneal bevacizumab in managing refractory malignant ascites and explored the recommended dose of bevacizumab for further study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with refractory malignant ascites were enrolled. Bevacizumab was intraperitoneal administered weekly at an initial dose of 2.5\u2009mg\/kg, with dose escalation to 5 and 7.5\u2009mg\/kg performed following the standard \u201c3\u2009+\u20093\u201d rule. The total duration of treatment was 2 or 3 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between December 2013 and September 2014, 13 patients (2.5\u2009mg\/kg, n\u2009=\u20094; 5\u2009mg\/kg, n\u2009=\u20093; 7.5\u2009mg\/kg, n\u2009=\u20096) with refractory malignant ascites were enrolled. Bevacizumab was well tolerated, and the most common treatment-related adverse events were abdominal pain (5\/13), abdominal distension (2\/13), and fatigue (2\/13). The dose-limiting toxicity at 7.5\u2009mg\/kg was grade 3 bowel obstruction (1\/13). The maximum tolerated dose (MTD) was not reached. The overall response and disease control rates were 7.7 and 61.5%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intraperitoneal bevacizumab safe and well tolerated for treating malignant ascites, and the MTD was not reached at doses of 2.5 to 7.5\u2009mg\/kg. Intraperitoneal bevacizumab at 7.5\u2009mg\/kg weekly is recommended for further study to verify its anti-tumor activity. Trial registration: Clinical Trials NCT01852409.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0300060520986664","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T11:17:30Z","timestamp":1613992650000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites"],"prefix":"10.1177","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-6344","authenticated-orcid":false,"given":"Furong","family":"Kou","sequence":"first","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"bibr1-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0109"},{"key":"bibr2-0300060520986664","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MPA.0000000000000290","volume":"44","author":"Takahara N","year":"2015","journal-title":"Pancreas"},{"key":"bibr3-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-1426-3"},{"key":"bibr4-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.04.014"},{"key":"bibr5-0300060520986664","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i39.10936"},{"key":"bibr6-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-012-0396-6"},{"key":"bibr7-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2015.09.074"},{"key":"bibr8-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000809"},{"key":"bibr9-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3262-7"},{"key":"bibr10-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-017-1872-1"},{"key":"bibr11-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01074-X"},{"key":"bibr12-0300060520986664","doi-asserted-by":"publisher","DOI":"10.2165\/11209040-000000000-00000"},{"key":"bibr13-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4198-0"},{"key":"bibr14-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9972-2"},{"key":"bibr15-0300060520986664","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S51916"},{"key":"bibr16-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.11.005"},{"key":"bibr17-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0302-9"},{"key":"bibr18-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl143"},{"key":"bibr19-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.9043"},{"key":"bibr20-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.04.028"},{"key":"bibr21-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.05.004"},{"key":"bibr22-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23707"},{"key":"bibr23-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29297"},{"key":"bibr24-0300060520986664","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i31.5051"},{"key":"bibr25-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006278"},{"key":"bibr26-0300060520986664","doi-asserted-by":"publisher","DOI":"10.2174\/1389450117666160502150237"},{"key":"bibr27-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.11.039"},{"key":"bibr28-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.843"},{"key":"bibr29-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9351-4"},{"key":"bibr30-0300060520986664","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0292-1"},{"key":"bibr31-0300060520986664","first-page":"1313","volume":"36","author":"Jiang L","year":"2016","journal-title":"Anticancer Res"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060520986664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0300060520986664","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060520986664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:48:04Z","timestamp":1777459684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0300060520986664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1177\/0300060520986664"],"URL":"https:\/\/doi.org\/10.1177\/0300060520986664","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"article-number":"0300060520986664"}}